Journal Article

Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice

Lori R. Kisley, Bradley S. Barrett, Lori D. Dwyer-Nield, Alison K. Bauer, David C. Thompson and Alvin M. Malkinson

in Carcinogenesis

Volume 23, issue 10, pages 1653-1660
Published in print October 2002 | ISSN: 0143-3334
Published online October 2002 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/23.10.1653
Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Cyclooxygenase (COX) enzyme expression is elevated in human and rodent lung tumors, and non-steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin reduce lung tumor formation in mice. These observations, along with the well-characterized protection that NSAID treatment engenders for colon cancer, have prompted clinical trials testing whether celecoxib, a COX-2-specific inhibitor, can prevent lung cancer development in populations at high risk. Protection by celecoxib in murine models of pulmonary inflammation and lung tumorigenesis has not yet been evaluated, however, and we now report such studies. Chronic administration of butylated hydroxytoluene (BHT) to mice stimulates pulmonary inflammation characterized by vascular leakage and macrophage infiltration into the air spaces, increased PGE2 production, and translocation of 5-lipoxygenase (5-LO) from the cytosol to the particulate fraction. Dietary celecoxib limited macrophage infiltration, abrogated PGE2 production and reduced particulate 5-LO content. Celecoxib and aspirin were ineffective at preventing lung tumorigenesis in a two-stage carcinogenesis protocol in which 3-methylcholanthrene administration is followed by chronic BHT. Celecoxib also did not reduce the multiplicity of lung tumors after induction by urethane; lung tumors in celecoxib-treated mice were larger than those in mice that did not receive celecoxib. Tumors induced in celecoxib-fed mice contained 60% less PGE2 than tumors in mice fed control diets, so reducing lung PGE2 levels was insufficient to prevent lung tumor formation. As the production of eicosanoids in addition to PGE2 is also inhibited by celecoxib, and as celecoxib has COX-independent interactions, its effects on tumor formation may vary in different organ systems.

Keywords: AC, adenocarcinoma; ASA, acetyl salicylic acid; BP, benzo(a)pyrene; BAL, bronchoalveolar lavage; BHT, butylated hydroxy-toluene; CCXB, celecoxib; COX, cyclooxygenase; ENU, ethylnitrosurea; 5-LO, 5-lipoxygenase; MCA, 3-methylcholanthrene; NNK, nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NDGA, nodihydroguaiacetic acid; NSCLC, non small cell lung cancer; NSAIDs, nonsteroidal anti-inflammatory drugs; PPAR, peroxisome proliferator-activated receptor.

Journal Article.  5690 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.